Clinical Trials Browser

INDUSTRY × trametinib × 30 days × Clear all

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT04892017 2026-04-08

Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors

Phase 1 Terminated

91 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT03975829 2026-04-02

Pediatric Long-Term Follow-up and Rollover Study

Phase 4 Active not recruiting

163 enrolled

CNSMyeloid

Astrocytoma, Ganglioneuroma, Glioblastoma, Glioma, Histiocytosis, Langerhans-Cell, Neuroblastoma, Neurofibromatosis 1, Oligodendroglioma, Ganglioglioma, Neurocytoma, Neurofibroma, Plexiform

NCT07468071 2026-04-02

KontRASt-R

Phase 1/2 Not yet recruiting

40 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT03340506 2026-04-01

Dabrafenib and/or Trametinib Rollover Study

Phase 4 Recruiting

100 enrolled

CNSDermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Glioma, Lung Neoplasms, Melanoma

NCT03899155 2026-04-01

Pan Tumor Rollover Study

Phase 2 Recruiting

1,500 enrolled

Tumor-Agnostic

Neoplasms

Clinical Trials

KontRASt-03

Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors

Pediatric Long-Term Follow-up and Rollover Study

KontRASt-R

Dabrafenib and/or Trametinib Rollover Study

Pan Tumor Rollover Study